Skip to main content
. 2023 Mar 17;12(3):502–514. doi: 10.21037/tcr-22-1855

Table 5. Univariate and multivariate analyses of PCa-associated factors in patients with PSA levels of 2.5–20.0 ng/mL.

Variables Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age (years)
   <68.5
   ≥68.5 3.20 (1.921–5.321) <0.001 3.51 (1.920–6.417) <0.001
PSA (ng/mL)
   <6.315
   ≥6.315 3.43 (2.026–5.814) <0.001 0.656
TPV (mL)
   ≥34.50
   <34.50 3.62 (2.137–6.133) <0.001
PZV (mL)
   ≥19.85
   <19.85 2.31 (1.413–3.785) 0.001
PZ-PSAD (ng/mL2)
   <0.368
   ≥0.368 5.04 (2.991–8.475) <0.001 0.370
TZ-PSAD (ng/mL2)
   <0.353
   ≥0.353 5.47 (3.229–9.268) <0.001 2.26 (1.019–4.993) 0.045
PSAD (ng/mL2)
   <0.218
   ≥0.218 8.16 (4.612–14.419) <0.001 3.51 (1.306–9.415) 0.013

PCa, prostate cancer; PSA, prostate-specific antigen; OR, odds ratio; CI, confidence interval; TPV, total prostate volume; PZV, peripheral zone volume; PZ-PSAD, peripheral zone prostate-specific antigen density; TZ-PSAD, transition zone prostate-specific antigen density.